IHE

Featured

Pfizer, Actavis Rumor, Inversion Turn Attention to Pharma ETFs

By Tom LydonSeptember 24, 2014

Featured

iShares Announces Modest Fee Cuts on 24 ETFs

By Tom LydonSeptember 3, 2014

Featured

ETFs for Hedge Funds’ Favorite Pharma Stocks

By Tom LydonAugust 25, 2014

Featured

Investors Flee Once Hot Health Care ETFs

By Todd ShriberApril 28, 2014

Featured

Bill Ackman Might Like These Pharma ETFs

By Todd ShriberApril 22, 2014

Featured

Deal for Forest Fantastic for Pharma ETFs

By Todd ShriberFebruary 18, 2014

Featured

Fun With Pharma ETFs

By Todd ShriberJanuary 21, 2014

Featured

Pharma ETFs Could Flatline on Obamacare Bust

By Max ChenNovember 20, 2013

Featured

Help From the Hill Could Add to Pharma ETFs’ Gains

By Tom LydonNovember 16, 2013

Featured

Election Could Make or Break Health Care ETFs

By Tom LydonSeptember 18, 2012

Featured

Pharmaceutical ETFs: A Defensive Play in 2012?

By Tom LydonApril 25, 2012

Featured

Utilities, Consumer and Pharma ETFs Lead 2011

By Tom LydonDecember 19, 2011

Featured

Sector ETF Performance in 2011

By Tom LydonNovember 6, 2011

Featured

Lower-Risk Stock ETFs to Consider

By Tom LydonJuly 25, 2011

Featured

Biotech ETFs: Orexigen Hit By Regulatory Hammer

By Tom LydonJune 3, 2011

Featured

Healthcare, Pharma ETFs Hit by Pfizer Decline

By John SpenceMay 3, 2011

Featured

Pfizer to Weigh on Pharma, Healthcare ETFs

By John SpenceMay 3, 2011

Featured

Pharma, Healthcare ETFs in Focus on M&A Talk, Earnings

By John SpenceApril 18, 2011

Previous 1 2 3 4 5 Next